Glucotrack Business Summary

Glucotrack, Inc. (GCTK) is a clinical-stage medical technology company primarily focused on the development and commercialization of its proprietary long-term implantable Continuous Blood Glucose Monitor (CBGM). As of February 2026, the company is pre-revenue, operating as a pure R&D play with a business model centered on the future high-margin sale of implantable sensors and recurring revenue from replacement hardware and data services. Unlike traditional Continuous Glucose Monitors (CGMs) that measure interstitial fluid, Glucotrack’s CBGM utilizes an intravascular lead to measure glucose directly from the blood, aiming to eliminate the 15-20 minute lag time associated with current standards of care. The device is designed for a multi-year lifespan—targeting up to three years of continuous use without on-body wearable components—positioning it as a disruptive alternative to short-term sensors. Glucotrack competes directly with industry leaders Dexcom, Abbott Laboratories, and Medtronic, as well as Senseonics Holdings, the latter of which offers the only other FDA-cleared implantable CGM, though Glucotrack seeks to significantly exceed Senseonics' 180-day sensor longevity. The company is led by President and CEO Paul V. Goode, PhD, a medical device veteran with a deep pedigree in diabetes technology, having previously held leadership roles at Dexcom and MiniMed (acquired by Medtronic). The executive team was significantly bolstered in early 2025 with the appointments of Chief Financial Officer Peter C. Wulff, who brings over 35 years of life sciences financial experience from firms like JenaValve and Alphatec Spine, and Vice President of Regulatory Affairs Ted Williams, an expert in Class III implantable CGMs formerly of GlySens. While the company was co-founded by Avner Gal and David Malka, its current strategic direction is driven by this specialized leadership tier and a board that includes Victoria E. Carr-Brendel, PhD, a former executive at Boston Scientific. Glucotrack’s capital structure is heavily influenced by institutional investor Armistice Capital, which holds a significant stake and has provided the financing necessary to fund the company’s transition toward its planned 2026 FDA Investigational Device Exemption (IDE) submission.